期刊文献+
共找到1篇文章
< 1 >
每页显示 20 50 100
Impact of preformed donor-specific antibodies against HLA class Ⅰ on kidney graft outcomes:Comparative analysis of exclusively anti-Cw vs anti-A and/or-B antibodies 被引量:1
1
作者 Sofia Santos Jorge Malheiro +10 位作者 Sandra Tafulo Leonídio Dias Rute Carmo susana sampaio Marta Costa Andreia Campos Sofia Pedroso Manuela Almeida La Salete Martins Castro Henriques António Cabrita 《World Journal of Transplantation》 2016年第4期689-696,共8页
AIM To analyze the clinical impact of preformed antiH LA-Cw vs antiH LA-A and/or-B donor-specific antibodies(DSA) in kidney transplantation.METHODS Retrospective study, comparing 12 patients transplanted with DSA excl... AIM To analyze the clinical impact of preformed antiH LA-Cw vs antiH LA-A and/or-B donor-specific antibodies(DSA) in kidney transplantation.METHODS Retrospective study, comparing 12 patients transplanted with DSA exclusively antiH LA-Cw with 23 patients with preformed DSA antiH LA-A and/or B.RESULTS One year after transplantation there were no differencesin terms of acute rejection between the two groups(3 and 6 cases, respectively in the DSA-Cw and the DSA-A-B groups; P = 1). At one year, eG FR was not significantly different between groups(median 59 mL /min in DSA-Cw group, compared to median 51 mL /min in DSA-A-B group, P = 0.192). Moreover, kidney graft survival was similar between groups at 5-years(100% in DSA-Cw group vs 91% in DSA-A-B group, P = 0.528). The sole independent predictor of antibody mediated rejection(AMR) incidence was DSA strength(HR = 1.07 per 1000 increase in MFI, P = 0.034). AMR was associated with shortened graft survival at 5-years, with 75% and 100% grafts surviving in patients with or without AMR, respectively(Log-rank P = 0.005).CONCLUSION Our data indicate that DSA-Cw are associated with an identical risk of AMR and impact on graft function in comparison with "classical" class I DSA. 展开更多
关键词 Donor-specific ANTIBODIES ANTIBODY-MEDIATED rejection ANTI human LEUKOCYTE antigen classⅠ AntiHLACw ANTIBODIES Graft survival SOLID-PHASE immunoassays
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部